CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

The clinical-stage company on Monday said that, following "highly encouraging" 16-week extension results from the Phase 2b trial, it believes it has established proof-of-concept for neflamapimod as a ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), ...

My colleagues in the DLB clinical community and I look forward to working with CervoMed and regulatory authorities to advance neflamapimod through phase 3 and the regulatory approval process.” ...

(MENAFN- GlobeNewsWire - Nasdaq) A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo ...

“Following the highly encouraging 16-week extension results from our Phase 2b RewinD-LB trial, we believe we have established proof-of-concept for neflamapimod as a potential treatment for DL ...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial’s primary ...

CervoMed's neflamapimod capsules show increased efficacy in treating dementia with Lewy bodies, with promising safety results and lower fall incidence. The new capsules led to higher plasma ...